anti ifn λ2 3 antibody Search Results


anti ifn λ2 3  (R&D Systems)
94
R&D Systems anti ifn λ2 3
Anti Ifn λ2 3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ifn+%CE%BB2+3+antibody/Mouse+IL-28A%2FB+(IFN-lambda+2%2F3)+Antibody/bio_rxiv__2022__03__04__482997-196-32-34
Average 94 stars, based on 1 article reviews
anti ifn λ2 3 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
ifn λ2 3  (R&D Systems)
94
R&D Systems ifn λ2 3
Ifn λ2 3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ifn+%CE%BB2+3+antibody/Mouse+IL-28A%2FB+(IFN-lambda+2%2F3)+Antibody/bio_rxiv__376103-211-9-10
Average 94 stars, based on 1 article reviews
ifn λ2 3 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti ly6g antibody  (Bio X Cell)
96
Bio X Cell anti ly6g antibody
Fig. 5 <t>Anti-Ly6G</t> treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone <t>1A8</t> <t>#BE0075-1,</t> BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.
Anti Ly6g Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ifn+%CE%BB2+3+antibody/InVivoMAb+anti-mouse+Ly6G+Ly6C/pm36227523-280-24-29
Average 96 stars, based on 1 article reviews
anti ly6g antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
antibodies against mouse rantes  (R&D Systems)
90
R&D Systems antibodies against mouse rantes
Fig. 5 <t>Anti-Ly6G</t> treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone <t>1A8</t> <t>#BE0075-1,</t> BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.
Antibodies Against Mouse Rantes, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ifn+%CE%BB2+3+antibody/Mouse+CCL5%2FRANTES+Antibody/bio_rxiv__376103-211-0-4
Average 90 stars, based on 1 article reviews
antibodies against mouse rantes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mip 1α  (R&D Systems)
93
R&D Systems mip 1α
Fig. 5 <t>Anti-Ly6G</t> treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone <t>1A8</t> <t>#BE0075-1,</t> BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.
Mip 1α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ifn+%CE%BB2+3+antibody/Mouse+CCL3%2FMIP-1+alpha+Antibody/bio_rxiv__376103-211-6-7
Average 93 stars, based on 1 article reviews
mip 1α - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 5 Anti-Ly6G treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone 1A8 #BE0075-1, BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.

Journal: Inflammation

Article Title: The Influenza-Induced Pulmonary Inflammatory Exudate in Susceptible Tpl2-Deficient Mice Is Dictated by Type I IFN Signaling.

doi: 10.1007/s10753-022-01736-8

Figure Lengend Snippet: Fig. 5 Anti-Ly6G treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone 1A8 #BE0075-1, BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.

Article Snippet: On days 5 and 7 post infection, the mice were administered intraperitoneally (i.p.) either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell), 200 μg anti-Ly6G antibody (clone 1A8 #BE0075-1, BioXCell), or 2.5 μg anti-IFN-λ2/3 antibody (clone 244,716 #MAB17892, R&D Systems).

Techniques: Infection, Control